We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
OP172 Do Expedited Regulatory Pathways Affect Time To Health Technology Assessment Decision?
- Authors
Cai, Jesmine; Wang, Tina; McAuslane, Neil; Liberti, Lawrence
- Abstract
Introduction: In an effort to speed the assessment of new medicines while maintaining the quality of the regulatory review, facilitated regulatory pathways (FRPs) have been introduced in many countries. In this study, the effects of FRPs (expedited and conditional reviews) were investigated in terms of their influence on HTA outcomes and timing. Methods: HTA recommendations issued between 2014 and 2016 were collected from CADTH (Canada), HAS (France), IQWIG (Germany), SMC (Scotland) and TLV (Sweden) for 90 internationalized medicines (new active substances approved between 2012 and 2016 by all regulatory agencies in the five jurisdictions). The HTA decisions were then classified into the following categories: positive, positive with restrictions, negative and multiple. Results: Of this cohort of internationalized medicines that received an HTA recommendation, 31 percent in Canada and 28 percent in Europe were approved via a FRP. With the exception of Scotland, expedited medicines were more likely to be appraised within a year from regulatory approval and had a shorter median time between regulatory approval to HTA recommendation than standard medicines. The largest difference was seen in Sweden, where medicines were 66.5 days faster than standard pathways when it underwent the expedited pathways. Compared to standard pathways, there were generally a higher proportion of positive and positive with restrictions recommendations when expedited pathways were used. Germany reported the largest proportional difference (31 percent) between the two pathways. Conclusions: Medicines being designated for an expedited review pathway show a reduced time from regulatory approval to HTA decision. This finding suggests there is an alignment between regulators and HTA agencies on which medicines require expedited HTA pathways; however, from this data it cannot be assessed whether the reduced time from approval to HTA decision is attributed to the company strategy, HTA review time or both. Further investigation is required.
- Subjects
EUROPE; SWEDEN; SCOTLAND; TECHNOLOGY assessment; MEDICAL technology; REGULATORY approval; MEDICAL standards; GOVERNMENT agencies
- Publication
International Journal of Technology Assessment in Health Care, 2018, Vol 34, p63
- ISSN
0266-4623
- Publication type
Abstract
- DOI
10.1017/S0266462318001745